India, Jan. 6 -- Biocon Biologics and subsidiary of Biocon will introduce three new oncology biosimilars, further strengthening its comprehensive cancer portfolio. The company will also highlight its plans to integrate as a wholly owned subsidiary of Biocon and the vital role of biosimilars in expanding access to affordable medicines at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco.The company is set to unveil three new biosimilar oncology assets'Trastuzumab/Hyaluronidase (Herceptin' SC/Herceptin HYLECTA'), Nivolumab (Opdivo'), and Pembrolizumab (Keytruda')'at the 2026 J.P. Morgan Healthcare Conference. With these new oncology assets, including two PD-1 inhibitors, Biocon Biologics will have one of the most comprehensiv...